A small molecule the body forms from arginine, sold as its sulfate salt. Only pain from compressed or damaged nerves has controlled human support, with substantial improvement. Mood, memory, inflammation and blood sugar rest on animal work or a few patients. Gastrointestinal upset appears only at the highest dose tested. Almost all human work comes from the product's seller. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Seated and standing blood pressure | 105–120 / 65–80 mmHg seated; under 10 mmHg standing drop | Detects the predicted additive blood-pressure fall |
| Resting heart rate | 55–70 bpm | Companion signal to an imidazoline-mediated pressure fall |
| Fasting glucose | 75–86 mg/dL | Covers the theoretical insulin release at imidazoline sites |
| Creatinine with eGFR | eGFR above 90 mL/min/1.73 m² | Kidney cation transporters set exposure |
| Alanine and aspartate aminotransferase | Below 25 U/L (men), 20 U/L (women) | Exposure past 21 days is unstudied |
| Plasma agmatine | No established target; track from own baseline | Would confirm absorption |
| Validated pain score (Neuropathic Pain Questionnaire or visual analogue scale) | Fall of at least 30% from own baseline | Defines success for the one controlled benefit |
Cadence: Baseline panel before the first dose; blood pressure and heart rate at day 3 and 14; symptom score at day 14 and week 8; kidney and liver panel at 12 weeks, then every 6–12 months beyond 21 days